SCHEMBL2431522

SCHEMBL2431522

Fc1ccc(-c2ccc[c]c2C(F)(F)F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP1 P22413 1/20 0.39
PTGS2 P35354 2/20 0.36
PTGS1 P23219 1/20 0.36
PDK2 Q15119 1/20 0.34
HTR7 P34969 2/20 0.34
HTR1A P08908 1/20 0.34
NTRK1 P04629 2/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
NR4A2 P43354 1/20 0.33
HSD11B1 P28845 1/20 0.32
KDR P35968 2/20 0.32
DAPK3 O43293 1/20 0.32
PRKD3 O94806 1/20 0.32
MAP4K4 O95819 1/20 0.32
PAK4 O96013 1/20 0.32
ABL1 P00519 1/20 0.32
LCK P06239 1/20 0.32
CSF1R P07333 1/20 0.32
RET P07949 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15663248 0.85 KIF11 (0.45) ENPP1POLBKDM4E
SCHEMBL455371 0.85 ALDH1A1 (0.40) ENPP1HSD11B1POLB
SCHEMBL28126044 0.84 ALDH1A1 (0.34) ENPP1SLC6A3KDRLCKCSF1R
SCHEMBL2015762 0.84 HTR1A (0.35) HTR7HTR1A
SCHEMBL18547650 0.84 KIF11 (0.42) PDK2ABL1RPS6KA3
SCHEMBL10476025 0.84 KLRK1 (0.36) ENPP1PTGS2PTGS1PDK2HTR7
SCHEMBL3678971 0.84 ENPP1 (0.40) ENPP1PTGS2PDK2HSD11B1POLB
SCHEMBL2430766 0.81 NT5E (0.41) PDK2HTR7HTR1AMAP4K4PRKACA
SCHEMBL2428521 0.81 HSD17B1 (0.34) PDK2
SCHEMBL9229761 0.80 ABL1 (0.45) ENPP1PTGS2PDK2HTR7HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060142378-A1 AMINO-FUNCTIONALIZED 1,2,4-TRIOXANES USEFUL AS ANTIMALARIAL AGENTS AND PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2006-06-29 US claimed
WO-2013182433-A1 A PROCESS USING GRIGNARD REAGENTS BASF SE (DE) 2013-12-12 WO disclosed
EP-2547687-A1 A PROCESS USING GRIGNARD REAGENTS BASF SE (DE) 2013-01-23 EP disclosed
EP-2513067-A1 METHOD FOR PRODUCING TRIAZOLINTHIONE DERIVATIVES AND INTERMEDIATES THEREOF BASF SE (DE) 2012-10-24 EP disclosed
WO-2011113820-A1 A PROCESS USING GRIGNARD REAGENTS BASF SE (DE) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142378-A1 AMINO-FUNCTIONALIZED 1,2,4-TRIOXANES USEFUL AS ANTIMALARIAL AGENTS AND PROCESS FOR PREPARATION THEREOF CYP4X1, CYP4B1, ABL1 ENPP1 1871/4885PTGS2 3589/4885PTGS1 3724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.